HC Wainwright Issues Positive Forecast for Context Therapeutics (NASDAQ:CNTX) Stock Price

Context Therapeutics (NASDAQ:CNTX) had its price objective hoisted by research analysts at HC Wainwright from $4.00 to $5.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 342.48% from the company’s current price.

Several other equities research analysts have also recently issued reports on CNTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, October 8th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, October 16th. Guggenheim began coverage on Context Therapeutics in a research note on Thursday, September 18th. They set a “buy” rating and a $5.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on Context Therapeutics in a research note on Thursday, October 2nd. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.40.

Context Therapeutics Stock Performance

NASDAQ:CNTX opened at $1.13 on Thursday. Context Therapeutics has a one year low of $0.49 and a one year high of $2.32. The stock has a market cap of $101.36 million, a PE ratio of -3.14 and a beta of 1.94. The stock has a 50 day moving average price of $1.06 and a 200 day moving average price of $0.85.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Context Therapeutics stock. Clear Harbor Asset Management LLC lifted its stake in Context Therapeutics Inc. (NASDAQ:CNTX) by 60.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 92,804 shares of the company’s stock after purchasing an additional 35,000 shares during the period. Clear Harbor Asset Management LLC owned about 0.10% of Context Therapeutics worth $90,000 at the end of the most recent quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.